Telemetric Arrhythmia and Syncope Diagnosis - Evaluation of Arrhythmia Treatment Efficacy (TELEMARC 4)

• Occurence of atrial fibrillation [ Time Frame: 14 days since the start of monitoring ] [ Designated as safety issue: No ]
  Confirmation of indication for catheter ablation of atrial fibrillation by detection of incidence of AF event during 14 days ECG monitoring
  
  

• Therapy efficacy analysis [ Time Frame: 14 days ] [ Designated as safety issue: No ]
  The mean atrial fibrillation burden reduction
  
  
• Indication for treatment other than catheter ablation [ Time Frame: 14 days ] [ Designated as safety issue: No ]

  Confirmation of indication for treatment other than catheter ablation such as: pacemaker or pharmacotherapy by detetion of:

  1. arrhythmia other than AF qualifying for treatment
  2. Bradycardia < 40 BPM
  3. Pauses > 2,5 s on sinus rhythm or > 3,5 on AF
  
  
• Correlation of patient self assessment based on the Quality of Life questionnaire and European Heart Rhythm Association (EHRA) scale with cardiac arrhythmia occurrence. [ Time Frame: 14 days ] [ Designated as safety issue: No ]
  
• Evaluation of stroke and bleeding risk factors incidence based on scores proposed in the European Society of Cardiology (ESC) guidelines: CHADS2VASC2 and HAS-BLED [ Time Frame: 14 days ] [ Designated as safety issue: No ]
  

Non-invasive methods enabling long-term ECG monitoring in patients with paroxysmal symptoms, such as tachycardia or palpitations increase the probability of detecting infrequent but dangerous events with profound clinical significance. Patients with recommendation for the first catheter ablation of Paroxysmal Atrial Fibrillation in the reference center will be included in the study. Eligible patients will have 14-day telemetric ECG monitoring. Based on detected arrhythmia events, patient's medical history and available documentation the most appropriate treatment will be recommended. Patients will undergo invasive procedures of ablation or pacemaker implantation or can be treated pharmacologically. After the invasive treatment or initiation of pharmacotherapy the 14-day telemetric ECG monitoring will be repeated to assess efficacy of the treatment.

Patients with no record of arrhythmia requiring treatment during the first 14 days ECG monitoring will terminate participation in the study. The referring physician will be informed. Further diagnosis or treatment should be performed at the referring physician's center according to the best clinical practice.